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Abstract: Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with
indolent course. Liver transplantation for local disease is the treatment of choice. In the
metastatic setting there is no consensus regarding the appropriate systemic treatment.
We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE)
treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable
Disease (SD) as a response, after the completion of six cycles of this combination therapy.
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Introduction
Epithelioid hemangioendothelioma (EHE) is a rare vascular sarcoma of intermedi-
ate malignant potential with an indolent course.1 Hepatic epithelioid hemangioen-
dothelioma (hEHE) presents usually with multifocal lesions and unpredictable
progression. Recurrence and metastases to several distant sites such as bones,
lungs and soft tissues can occur at any time.1
Recent development in the diagnosis of these tumors is the identification of two
specific fusion genes; WWTR1(TAZ)-CAMTA1 and YAP1-TFE3, which are
pathognomonic for EHE.2–4 Further, they shed light on the biological mechanism
involved in the development of these tumors. Both TAZ and YAP are co-transcrip-
tion factors, being the principal effectors of Hippo signaling pathway. TAZ and
YAP via TEAD transcription factor alter the expression of their downstream targets.
Interestingly, Hippo pathway gains a pivotal role in the tumorigenesis of hEHE.5,6
Treatment of hEHE is still surgical. For localized disease; hepatic transplanta-
tion is the treatment of choice.7,8 However, when metastatic disease exists; systemic
treatment should be considered.9,10 Regarding the selection of the most appropriate
systemic treatment there is no consensus. European Society of Medical Oncology
(ESMO) and National Comprehensive Cancer network (NCCN) guidelines do not
recommend any specific regimens for Stage IV EHE and clinicians treat those
patients like any other patient with a soft tissue sarcoma.10–12 Anthracycline-based
chemotherapy is the standard of choice for 1st line treatment. Recently, a Phase II
randomized trial showed that the addition of Olaratumab (a anti PDGFRα mono-
clonal antibody) to standard Doxorubicin resulted in a 11.8 month survival benefit
as compared to Doxorubicin monotherapy in patients with advanced soft tissue
sarcoma of various histology.13 This combination regimen was incorporated in both
ESMO and NCCN guidelines, despite original skepticism. However, according to
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a recent press release by the Olaratumab manufacturer, the
primary endpoint of overall survival (OS) benefit with the
combination of Olaratumab plus Doxorubicin was not met
for patients with advanced or metastatic soft tissue sar-
coma in the Phase III ANNOUNCE clinical trial.14
Based on the initial indication of the drug, we present
herein two cases of hEHE treated with the combination of
Doxorubicin and Olaratumab in the 1st line setting.
Both patients have provided written informed consent
to have the case details and the accompanying images. The
ethics committee of Alexandra General Hospital approved
the study and provided approval to publish the case details
Patients and Methods
Patient 1
A 33-year-old male presented with the diagnosis of meta-
static hEHE. In a routine blood test, alkaline phosphatase
and γ-glutamyl transferase were found over the highest
normal level as an incidental finding. Subsequent ima-
ging with Ultrasound of the abdomen revealed multiple
hepatic lesions. Colonoscopy and gastroscopy were nor-
mal. A CT scan of the chest and the abdomen was
performed revealing a lytic lesion of the 5th right rib
and confirming the multiple hepatic lesions. Brain MRI
showed a lytic lesion of the clivus bone. Imaging was
completed with a PET CT which confirmed the lesions
described from previous tests. Biopsy of the hepatic
lesions favored the diagnosis hEHE.
The patient requested consultation from Cleveland
Clinic, Cleveland, OH, USA, where a diagnosis of
YAP1/TFE3 fused EHE was made based on negative
CAMTA1 and diffuse strongly positive nuclearTFE3
immunostain in tumor cells. The patient was treated with
the combination of Doxorubicin (75mg/m2)-Olaratumab
(15mg/kg) for six cycles and continued with Olaratumab
(15mg/kg) maintenance until the removal of the product
from the market. The patient had no adverse effects from
the treatment. Restaging with CT scans after the comple-
tion of the six cycles of chemotherapy revealed SD. In
addition, a PET CT was performed and revealed decreased
absorption of 18-FDG of the known lesions, indicative of
Partial Response (PR) (Figure 1).
Patient 2
A 62-year-old male, receiving chronic treatment for
chronic obstructive pulmonary disease, presented with
imaging that showed multiple hepatic lesions. He has
Figure 1 FDG PET/CT of patient 1. Upper line showing clivus, liver and rib lesions before therapy and lower line showing the same lesions after the administration of 6
cycles of Doxorubicin plus Olaratumab. Arrows highlight the lesions.
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been diagnosed with testicular seminoma 20 years ago and
had received several lines of treatment for advanced dis-
ease including 4 cycles of Bleomycin, Etoposide,
Cisplatin (BEP), 4 cycles of Vepeside, Ifosfamide,
Cisplatin (VIP), laparotomy, autologous transplantation
(June of 1998) and 7 cycles of Carboplatin-Etoposide
until May 2001. Since then, the patient remained in full
remission on annual or biannual follow up. CT scans of
abdomen and chest on September of 2018 revealed multi-
ple hepatic and lung lesions, further confirmed by imaging
with FDG PET/CT. CT guided needle biopsy of one of the
liver tumors favored the diagnosis of hEHE. Molecular
testing could not be performed due to limited remaining
diagnostic tissue material.
The patient was treated with the combination of
Doxorubicin (75mg/m2)-Olaratumab (15mg/kg) for 6 cycles.
The patient tolerated the treatment well, without any severe
adverse effects. Restaging with CTscans after the completion
of the 6 cycles of chemotherapy revealed SD, with some liver
tumors showing a decrease in diameter (Figure 2). The patient
tolerated therapy very well, with minor toxicities, mainly low
grade neutropenia, anemia and nausea. Granulocyte-colony
stimulation factor (GCSF) was administered for prophylaxis
in every cycle. Following the negative outcome of the
ANNOUNCE trial, it was decided to permanently discon-
tinue Olaratumab, since the patient did not experience
any clinically meaningful response and reimbursement
re-approval by Greek Public Insurance was also needed.
Results
Histopathology
In patient 1, histologic examination of the hepatic tumor
biopsy specimen showed medium-sized epithelioid tumor
cells with Ki67 Labeling index (LI) 8–10%, positive for
the endothelial markers CD34, CD31 and FVIII, and also
positive for EGFR, CD10 and Vimentin while HepPar1,
AFP, CEA, HHV-8 and K8/18 were negative, in keeping
with hEHE.
In patient 2, biopsy of one of the hepatic tumors
showed epithelioid neoplastic cells with an intravascular
pattern of growth and Ki67:<1%. Tumour cells were posi-
tive for CD31 and CD34, while keratins, OCT3/4, PLAP,
TTF1 and napsin A were negative in keeping with hEHE
and excluding metastatic seminoma.
Genetics
Real time PCR for the detection of WWTR1(TAZ)/CAMTA1
or YAP1/TFE3 was not informative for patient 1, while for
patient 2 there was no tissue material available for testing.
Discussion
HEHE is a rare vascular mesenchymal malignancy with
indolent course. Surgery is the treatment of choice when
this can lead to R0 excision. However, recurrence or
metastasis can occur at any time.
Surgical treatment of hEHE includes liver resection or
liver transplantation. Konstantinidis et al, in their study of
Figure 2 CT scans of patient 2. Upper line showing liver and lung lesions before therapy and lower line showing the same lesions after the administration of 6 cycles of
Doxorubicin plus Olaratumab. Arrows highlight the lesions.
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131 patients with angiosarcoma or hEHE compared liver
resection and transplantation, showing similar median over-
all survival (mOS).7 Especially for hEHE patients both
approaches had similar OS. The same conclusion was
reported from Mayo clinic, Rochester, MN, USA, in
a retrospective study of 30 patients with hEHE. However, it
must be highlighted that metastasis is not a contraindication
for liver transplantation. Smaller studies included hEHE
patients who underwent liver transplantation without extra-
hepatic disease, with very good outcomes.8,15–17
Systemic treatment for metastatic or progressed hEHE is
still not well established. There is no consensus on the
therapeutic algorithm which clinicians should follow.9
Chemotherapy with several regimens such as Doxorubicin
with or without ifosfamide, paclitaxel, epirubicin and dacar-
bazine, 5FU and mitomycin have been reported in small
series.18–22 Tyrosine kinase inhibitors such as pazopanib,
sunitinib, apatinib and sorafenib have been studied showing
PRor stabilization of the disease.23–28 Targeting angiogen-
esis with bevacizumab, interferon alpha 2b, thalidomide and
lenalidomide revealed contradictory results.29–33 Case
reports using metronomic cyclophosphamide and sirolimus
have also been published.34,35 The largest cohort of patients
reported includes 32 patients from the Royal Marsden
Hospital, London, UK, and depicts the heterogeneous ther-
apeutic approach of patients with these rare tumors ranging
from observation to systemic treatment including cytotoxic
regimens and targeted therapies.10
Recently, two specific fusion genes have been identi-
fied for EHE. WWTR1/CAMTA1 and YAP1/TFE3 are
pathognomonic for the diagnosis.2,3,36 WWTR1 (TAZ)
and YAP1 are two co-transcription factors, which repre-
sent the main molecular effectors of Hippo pathway.37
Both fusion genes consist of the N-terminus of WWTR1
and YAP1, containing the WW (tryptophan-tryptophan)
domain and TEAD binding domain respectively, fused
with the C-terminus of CAMTA1 and TFE3 transcription
factors.5 Targeting YAP and TAZ interaction with TEAD
or inhibiting Hippo pathway is a potent systemic treatment
for EHE. Clinical trials testing MEK inhibitor trametinib
and anti-microtubular agent eribulin are still running.
The addition of Olaratumab to Doxorubicin offered
a benefit of 11.8 months in OS; in a phase Ib-II clinical
trial comparing the doublet to Doxorubicin monotherapy.13
This advancement on the treatment of patients with soft
tissue sarcomas was highlighted by the inclusion of
Doxorubicin and Olaratumab combination in the recent
versions of both NCCN and ESMO guidelines.11,12
However, ESMO members have raised important criticism
regarding the unknown mechanism of action of
Olaratumab and the small benefit of PFS in the study.12
Unfortunately, Olaratumab did not meet the primary end-
points of OS both to overall population and the subgroup
of leiomyosarcomas.
We have treated two patients with metastatic hEHE
with the combination of Doxorubicin and Olaratumab on
1st line setting. Both patients had multifocal liver disease
and metastases making the option of liver transplantation
or hepatectomy impossible. Under the perspective of
a metastatic soft tissue sarcoma without any targeted thera-
pies approved, Olaratumab and Doxorubicin were chosen.
The phase Ib-II clinical trial did not include any patients
with EHE in the arm of Olaratumab.13 We are the first to
report real world data with the administration of this
combination to hEHE patients, with SD as best response
for both of them.
Real world data reporting the use of Olaratumab are
scarce. We have recently published the poor outcome of
Olaratumab administration to two patients with phyllodes
tumor of the breast.38 Herein, we report the potentially
beneficial addition of Olaratumab to the 1st line treatment
of metastatic hEHE.
The molecular mechanism by which PDGFR inhibition
works in EHE is unknown. Though, it is intriguing to
hypothesize that WWTR1/CAMTA1 and YAP1/TFE3
fusions can be associated to PDGFR inhibition.
Interestingly, PDGFR has been shown to crosstalk with
Hippo pathway. Smoot et al have described PDGFR reg-
ulation of YAP localization and expression via SFK kinase
phosphorylation in cholangiocarcinoma cell lines, xeno-
grafts and mice.6 Pharmacologic inhibition of PDGFR
signaling with crenolanib had a profound effect on Hippo
pathway’s downstream targets expression, such as CTGF
and Cyr61.6 All these data demonstrate a hint for
a possible interaction of PDGFR inhibition through
Olaratumab and –– the principal for the development of
EHE deregulation – Hippo pathway through the formation
of WWTR1/CAMTA1 and YAP1/TFE3 fusion genes.
It is reasonable to support that the response of our patients
was due to the action of Doxorubicin alone. However, in the
few cases reported and treated with Doxorubicin; best
response ranged from PR to SD or PD.10,18,39,40 A possible
explanation for the response of the two cases of metastatic
hEHE described herein; may be the biologic behavior of this
tumor type, which progresses slowly. Therapeutic targeting
of angiogenesis appears important; supporting a potential
Kyriazoglou et al Dovepress
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benefit of Olaratumab addition to the therapeutic approach of
this rare tumor.
Under the perspective of the recent failure of
Olaratumab to add any treatment benefit, a more critical
view to the design of sarcoma clinical trials is highlighted.
Histology-based reports, even with small number of cases,
due to the rarity of these neoplasms, are urgently needed.
Real world data with Olaratumab administration and sub-
analysis of the ANNOUNCE phase III Clinical trial are
highly awaited, in order to assess the effectiveness of this
new drug.
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